Elanco Receives USDA Approval for New Canine Dermatology Drug Befrena
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- New Drug Approval: Elanco's Befrena™ (tirnovetmab) has received USDA approval for treating canine allergic dermatitis, offering a dosing interval of 6 to 8 weeks, which enhances treatment flexibility compared to the 4 to 8 weeks of competitors.
- Market Leadership: Befrena is Elanco's second dermatology product approved in less than 18 months, further solidifying its leadership in canine dermatology and monoclonal antibodies, with a launch expected in the first half of 2026.
- Industry Demand: According to Elanco's report, 90% of dogs in the U.S. have experienced itching symptoms in the past year, with pet owners spending an average of $400 on over-the-counter remedies, highlighting the urgent need for effective treatment options.
- Veterinary Support: Nearly 70% of veterinarians are willing to stock new dermatology products to help more dogs find itch relief, and the approval of Befrena provides veterinarians with more safe and effective treatment options, addressing the market's demand for targeted therapies.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.13 USD with a low forecast of 23.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.760
Low
23.00
Averages
25.13
High
27.00
Current: 22.760
Low
23.00
Averages
25.13
High
27.00
About ELAN
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
